Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation.

Steffen PfeufferRene SchmidtFrederike Anne StraetenRefik PulChristoph KleinschnitzMarinus WieshuberDe-Hyung LeeRalf A LinkerSebastian DoerckVera StraetenSusanne WindhagenMarc PawlitzkiChristoph AufenbergMichael LangChristian EienbroekerBjörn TackenbergVolker LimmrothBrigitte WildemannJürgen HaasLuisa KlotzHeinz WiendlTobias RuckSven G Meuth

Published in: Journal of neurology (2018)

Our findings indicated particular advantages of ALEM compared to FTY in patients stopping NTZ.

Keyphrases

multiple sclerosis
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
peritoneal dialysis